Several studies strongly support the development of NOTCH1 inhibitors for targeted cancer therapy, particularly for T-ALL, where recurrent NOTCH1 mutations are common and cancer dependency has been well established (16–21). This evidence concerns the gene NOTCH1 and cancer.